Boundless persevered with the other drug, a CHK1 inhibitor BBI-355, as a monotherapy for oncogene-amplified solid tumors. But the clinical data showed signs of hematological toxicity that would have ...
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026Portfolio prioritization, including ...
FORT LAUDERDALE, Fla., Nov. 4, 2025 /PRNewswire/ -- Burdette Beckmann Inc. (BBI), a national sales agency leader in the confectionery industry, is proud to announce the acquisition of Action Sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results